147 related articles for article (PubMed ID: 37605297)
1. Discovery of a First-in-Class Degrader for the Lipid Kinase PIKfyve.
Li C; Qiao Y; Jiang X; Liu L; Zheng Y; Qiu Y; Cheng C; Zhou F; Zhou Y; Huang W; Ren X; Wang Y; Wang Z; Chinnaiyan AM; Ding K
J Med Chem; 2023 Sep; 66(17):12432-12445. PubMed ID: 37605297
[TBL] [Abstract][Full Text] [Related]
2. Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.
Han X; Zhao L; Xiang W; Miao B; Qin C; Wang M; Xu T; McEachern D; Lu J; Wang Y; Metwally H; Yang CY; Kirchhoff PD; Wang L; Matvekas A; Takyi-Williams J; Wen B; Sun D; Ator M; Mckean R; Wang S
J Med Chem; 2023 Jul; 66(13):8822-8843. PubMed ID: 37382562
[TBL] [Abstract][Full Text] [Related]
3. PIP5K1C phosphoinositide kinase deficiency distinguishes PIKFYVE-dependent cancer cells from non-malignant cells.
Roy A; Chakraborty AR; Nomanbhoy T; DePamphilis ML
Autophagy; 2023 Sep; 19(9):2464-2484. PubMed ID: 36803256
[TBL] [Abstract][Full Text] [Related]
4. Combined Inhibition of p38MAPK and PIKfyve Synergistically Disrupts Autophagy to Selectively Target Cancer Cells.
O'Connell CE; Vassilev A
Cancer Res; 2021 Jun; 81(11):2903-2917. PubMed ID: 33685990
[TBL] [Abstract][Full Text] [Related]
5. Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy.
Bao Y; Qiao Y; Choi JE; Zhang Y; Mannan R; Cheng C; He T; Zheng Y; Yu J; Gondal M; Cruz G; Grove S; Cao X; Su F; Wang R; Chang Y; Kryczek I; Cieslik M; Green MD; Zou W; Chinnaiyan AM
Proc Natl Acad Sci U S A; 2023 Dec; 120(49):e2314416120. PubMed ID: 38011559
[TBL] [Abstract][Full Text] [Related]
6. Intermittent inhibition of FYVE finger-containing phosphoinositide kinase induces melanosome degradation in B16F10 melanoma cells.
Kawaguchi K; Watanabe M; Furukawa S; Koga K; Kanamori H; Ikemoto MJ; Takashima S; Maeda M; Oh-Hashi K; Hirata Y; Furuta K; Takemori H
Mol Biol Rep; 2023 Jul; 50(7):5917-5930. PubMed ID: 37248430
[TBL] [Abstract][Full Text] [Related]
7. Discovery of ARD-69 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor (AR) for the Treatment of Prostate Cancer.
Han X; Wang C; Qin C; Xiang W; Fernandez-Salas E; Yang CY; Wang M; Zhao L; Xu T; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
J Med Chem; 2019 Jan; 62(2):941-964. PubMed ID: 30629437
[TBL] [Abstract][Full Text] [Related]
8. Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP/p300 PROTAC Degrader Capable of Achieving Tumor Regression.
Chen Z; Wang M; Wu D; Bai L; Xu T; Metwally H; Wang Y; McEachern D; Zhao L; Li R; Takyi-Williams J; Wang M; Wang L; Li Q; Wen B; Sun D; Wang S
J Med Chem; 2024 Apr; 67(7):5275-5304. PubMed ID: 38477974
[TBL] [Abstract][Full Text] [Related]
9. Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer.
Sun N; Kabir M; Lee Y; Xie L; Hu X; Velez J; Chen X; Kaniskan HÜ; Jin J
J Med Chem; 2023 Jan; 66(1):596-610. PubMed ID: 36538511
[TBL] [Abstract][Full Text] [Related]
10. A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis.
Sharma G; Guardia CM; Roy A; Vassilev A; Saric A; Griner LN; Marugan J; Ferrer M; Bonifacino JS; DePamphilis ML
Autophagy; 2019 Oct; 15(10):1694-1718. PubMed ID: 30806145
[TBL] [Abstract][Full Text] [Related]
11. Selective elimination of pluripotent stem cells by PIKfyve specific inhibitors.
Chakraborty AR; Vassilev A; Jaiswal SK; O'Connell CE; Ahrens JF; Mallon BS; Pera MF; DePamphilis ML
Stem Cell Reports; 2022 Feb; 17(2):397-412. PubMed ID: 35063131
[TBL] [Abstract][Full Text] [Related]
12. Discovery of a Highly Potent and Selective Dual PROTAC Degrader of CDK12 and CDK13.
Yang J; Chang Y; Tien JC; Wang Z; Zhou Y; Zhang P; Huang W; Vo J; Apel IJ; Wang C; Zeng VZ; Cheng Y; Li S; Wang GX; Chinnaiyan AM; Ding K
J Med Chem; 2022 Aug; 65(16):11066-11083. PubMed ID: 35938508
[TBL] [Abstract][Full Text] [Related]
13. PIKfyve inhibitor cytotoxicity requires AKT suppression and excessive cytoplasmic vacuolation.
Ikonomov OC; Altankov G; Sbrissa D; Shisheva A
Toxicol Appl Pharmacol; 2018 Oct; 356():151-158. PubMed ID: 30098992
[TBL] [Abstract][Full Text] [Related]
14. Identification of PIKfyve kinase as a target in multiple myeloma.
de Campos CB; Zhu YX; Sepetov N; Romanov S; Bruins LA; Shi CX; Stein CK; Petit JL; Polito AN; Sharik ME; Meermeier EW; Ahmann GJ; Armenta IDL; Kruse J; Bergsagel PL; Chesi M; Meurice N; Braggio E; Stewart AK
Haematologica; 2020 Jun; 105(6):1641-1649. PubMed ID: 31582538
[TBL] [Abstract][Full Text] [Related]
15. Identification of a selective BRD4 PROTAC with potent antiproliferative effects in AR-positive prostate cancer based on a dual BET/PLK1 inhibitor.
Hu R; Wang WL; Yang YY; Hu XT; Wang QW; Zuo WQ; Xu Y; Feng Q; Wang NY
Eur J Med Chem; 2022 Jan; 227():113922. PubMed ID: 34700270
[TBL] [Abstract][Full Text] [Related]
16. Autophagy Inhibition by Targeting PIKfyve Potentiates Response to Immune Checkpoint Blockade in Prostate Cancer.
Qiao Y; Choi JE; Tien JC; Simko SA; Rajendiran T; Vo JN; Delekta AD; Wang L; Xiao L; Hodge NB; Desai P; Mendoza S; Juckette K; Xu A; Soni T; Su F; Wang R; Cao X; Yu J; Kryczek I; Wang XM; Wang X; Siddiqui J; Wang Z; Bernard A; Fernandez-Salas E; Navone NM; Ellison SJ; Ding K; Eskelinen EL; Heath EI; Klionsky DJ; Zou W; Chinnaiyan AM
Nat Cancer; 2021 Sep; 2():978-993. PubMed ID: 34738088
[TBL] [Abstract][Full Text] [Related]
17. Akebia saponin E, as a novel PIKfyve inhibitor, induces lysosome-associated cytoplasmic vacuolation to inhibit proliferation of hepatocellular carcinoma cells.
Peng P; Jia D; Cao L; Lu W; Liu X; Liang C; Pan Z; Fang Z
J Ethnopharmacol; 2021 Feb; 266():113446. PubMed ID: 33031902
[TBL] [Abstract][Full Text] [Related]
18. Discovery of Highly Potent and Efficient PROTAC Degraders of Androgen Receptor (AR) by Employing Weak Binding Affinity VHL E3 Ligase Ligands.
Han X; Zhao L; Xiang W; Qin C; Miao B; Xu T; Wang M; Yang CY; Chinnaswamy K; Stuckey J; Wang S
J Med Chem; 2019 Dec; 62(24):11218-11231. PubMed ID: 31804827
[TBL] [Abstract][Full Text] [Related]
19. Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer.
Bi K; Cheng J; He S; Fang Y; Huang M; Sheng C; Dong G
J Med Chem; 2023 Jan; 66(1):1048-1062. PubMed ID: 36563407
[TBL] [Abstract][Full Text] [Related]
20. Discovery of A031 as effective proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader for the treatment of prostate cancer.
Chen L; Han L; Mao S; Xu P; Xu X; Zhao R; Wu Z; Zhong K; Yu G; Wang X
Eur J Med Chem; 2021 Apr; 216():113307. PubMed ID: 33652354
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
